FXR agonists have been studied in human trials in conditions such as primary biliary cholangitis, primary sclerosing cholangitis, and non-alcoholic steatohepatitis, which have shown encouraging results and good safety profiles [22,35]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.